Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials

Alméras N, Després JP, Villeneuve J, Demers MF, Roy MA, Cadrin C, Mottard JP, Bouchard RH (2004) Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 65:557–564 Aupperle P (2006) Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics. Am J Alzheimer’s Dis Other Demen 21:101–108 Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu LM, Jacoby R (2009) The dementia antipsychotic withdrawal trial (dart-ad): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8:151–157 Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, Kossakowski K, Yu LM, Juszczak E (2008) A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the dart-ad trial). PLoS Med 5:e76 Borenstein M HL, Higgins JPT, Rothstein H. (2006) Comprehensive meta-analysis version 2. www.meta-analysis.com Breitner JC (2006) Dementia–epidemiological considerations, nomenclature, and a tacit consensus definition. J Geriatr Psychiatry Neurol 19:129–136 Bullock R (2005) Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin 21:1–10 Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF (2001) A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in chinese dementia patients. Int J Geriatr Psychiatry 16:1156–1162 Cohen J (1969) Statistical power analysis for the behavioral sciences. Academic Press, New York Davidson M, Weiser M, Soares K (2000) Novel antipsychotics in the treatment of psychosis and aggression associated with dementia: a meta-analysis of randomized controlled clinical trials. Int Psychogeriatr 12:271–277 De Deyn P, Jeste DV, Swanink R, Kostic D, Breder C, Carson WH, Iwamoto T (2005) Aripiprazole for the treatment of psychosis in patients with alzheimer’s disease: a randomized, placebo-controlled study. J Clin Psychopharmacol 25:463–467 Devanand DP, Sackeim HA, Brown RP, Mayeux R (1989) A pilot study of haloperidol treatment of psychosis and behavioral disturbance in alzheimer’s disease. Arch Neurol 46:854–857 Dutche SK, Rattinger GB, Langenberg P, Chhabra PT, Liu X, Rosenberg PB, Leoutsakos JM, Simoni-Wastila L, Walker LD, Franey CS, Zuckerman IH (2014) Effect of medications on physical function and cognition in nursing home residents with dementia. J Am Geriatr Soc 62:1046–1055 Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634 Ellingrod VL, Schultz SK, Ekstam-Smith K, Kutscher E, Turvey C, Arndt S (2002) Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. Pharmacotherapy 22:1–5 FDA (2005) Fda public health advisory deaths with antipsychotics in elderly patients with behavioral disturbances. http://www.fda.gov/cder/drug/advisory/antipsychotics.htm Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198 Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF (2003) A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 64:726–730 Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, Bell CM, Lee PE, Fischer HD, Herrmann N, Gurwitz JH, Rochon PA (2007) Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146:775–786 Hedges LV (1994) The handbook of research synthesis. Russell Sage Foundation, New York Herrmann N, Lanctot KL (2006) Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned? Drug Saf 29:833–843 Herrmann N, Lanctot KL (2005) Do atypical antipsychotics cause stroke? CNS Drugs 19:91–103 Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560 Higgins JPT, Green S (2005) Cochrane handbook for systematic reviews of interventions 4.2.5. Wiley, Chichester Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J, Alzheimer’s Disease Neuroimaging Initiative (2013) Putting the alzheimer’s cognitive test to the test I: traditional psychometric methods. Alzheimer’s Dement J Alzheimer’s Assoc 9:S4–S9 Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J, Alzheimer’s Disease Neuroimaging Initiative (2013) Putting the alzheimer’s cognitive test to the test II: rasch measurement theory. Alzheimer’s Dement J Alzheimer’s Assoc 9:S10–S20 Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25:201–222 Kennedy J, Deberdt W, Siegal A, Micca J, Degenhardt E, Ahl J, Meyers A, Kaiser C, Baker RW (2005) Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate alzheimer’s dementia. Int J Geriatr Psychiatry 20:1020–1027 Lanctot KL, Best TS, Mittmann N, Liu BA, Oh PI, Einarson TR, Naranjo CA (1998) Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 59:550–561 Lawlor BA (2004) Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. J Clin Psychiatry 65(Suppl 11):5–10 McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T (1997) Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 314:266–270 Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s Dement J Alzheimer’s Assoc 9(63–75):e62 Rainer M, Haushofer M, Pfolz H, Struhal C, Wick W (2007) Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. Eur Psychiatry 22:395–403 Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, de Bie A, Rosenzweig P, Patat A, O’Hanlon JF (1999) Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol 19:209–221 Rosenberg PB, Mielke MM, Han D, Leoutsakos JS, Lyketsos CG, Rabins PV, Zandi PP, Breitner JC, Norton MC, Welsh-Bohmer KA, Zuckerman IH, Rattinger GB, Green RC, Corcoran C, Tschanz JT (2012) The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of alzheimer’s disease. Int J Geriatr Psychiatry 27:1248–1257 Saeedi H, Remington G, Christensen BK (2006) Impact of haloperidol, a dopamine d2 antagonist, on cognition and mood. Schizophr Res 85:222–231 Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H (2013) Dopamine d2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull 39:564–574 Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS (2007) Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 176:627–632 Schneider LS, Dagerman K, Insel PS (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14:191–210 Schneider LS, Dagerman KS, Insel P (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294:1934–1943 Steinberg M, Sheppard JM, Tschanz JT, Norton MC, Steffens DC, Breitner JC, Lyketsos CG (2003) The incidence of mental and behavioral disturbances in dementia: the cache county study. J Neuropsychiatry Clin Neurosci 15:340–345 Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A (2000) Olanzapine treatment of psychotic and behavioral symptoms in patients with alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The huge study group. Arch Gen Psychiatry 57:968–976 Streim JE, Porsteinsson AP, Breder CD, Swanink R, Marcus R, McQuade R, Carson WH (2008) A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with alzheimer disease. Am J Geriatr Psychiatry 16:537–550 Studyreport (2004) Cn 138005. http://www.clinicalstudyresults.org/ Studyreport (2005) F1d-mc-hgao http://www.clinicalstudyresults.org/ Studyreport (2005) F1d-mc-hgeu. http://www.clinicalstudyresults.org/ Studyreport (2005) F1d-mc-hgic. http://www.clinicalstudyresults.org/ Studyreport (2001) Ris-bel 14 http://www.clinicalstudyresults.org/ Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS (2008) Clinical symptom responses to atypical antipsychotic medications in alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 165:844–854 Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copenhaver M, Williams-Hughes C (2006) Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 14:767–776 Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano MWP, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal LJ (2000) Treatment of agitation in ad: a randomized, placebo-controlled clinical trial. Neurology 55:1271–1278 van Iersel MB, Zuidema SU, Koopmans RT, Verhey FR, Olde Rikkert MG (2005) Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events. Drugs Aging 22:845–858 Verhey FR, Verkaaik M, Lousberg R (2006) Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. Dement Geriatr Cogn Disord 21:1–8 Vernaleken I, Kumakura Y, Cumming P, Buchholz HG, Siessmeier T, Stoeter P, Muller MJ, Bartenstein P, Grunder G (2006) Modulation of [18f]fluorodopa (fdopa) kinetics in the brain of healthy volunteers after acute haloperidol challenge. NeuroImage 30:1332–1339 Veselinovic T, Schorn H, Vernaleken IB, Hiemke C, Zernig G, Gur R, Grunder G (2013) Effects of antipsychotic treatment on cognition in healthy subjects. J Psychopharmacol 27:374–385 Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS (2011) Cognitive effects of atypical antipsychotic medications in patients with alzheimer’s disease: outcomes from catie-ad. Am J Psychiatry 168:831–839 Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, Scheltens P, Tariska P, Winblad B (2007) Recommendations for the diagnosis and management of alzheimer’s disease and other disorders associated with dementia: Efns guideline. Eur J Neurol 14:e1–26 Zhong K, Tariot P, Minkwitz MC, NA D, Mintzer J (2004) Quetiapine for the treatment of agitation in elderly institutionalized patients with dementia: A randomized, double-blind trial. Presented at the 9th international conference on Alzheimer’s disease and related disorders, Philadelphia, PA, July 17–22, 2004 Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA (2007) Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res 4:81–93